相关实验视频

Updated: Jan 10, 2026

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

剖析抗体依赖增强调制通过Fc修饰的交叉中和的人类单克隆抗体

Subenya Injampa¹, Surachet Benjathummarak², Sujitra Keadsanti²

¹Faculty of Medicine, King Mongkut's Institute of Technology, Ladkrabang, Bangkok, Thailand.

|November 24, 2025

概括

研究人员开发了一种新的人类单克隆抗体,LALA-B3B9,可以中和所有四种登革热病毒血清型,而不会导致抗体依赖增强 (ADE). 这种抗体通过在体外抑制ADE,对登革热治疗具有前景.

科学领域:

免疫学免疫学免疫学
病毒学病毒学
治疗性抗体的开发方法

背景情况:

登革热病毒 (DENV) 感染对全球健康构成重大威胁,由于抗体依赖增强 (ADE),二次感染可能会恶化.
ADE涉及亚中和抗体,通过激活免疫细胞和补充,增加病毒感染的严重程度.
目前的治疗选择,特别是完全人类单克隆抗体,对于登革热缺乏.

研究的目的:

开发和描述一种新型的人类单克隆抗体 (HuMAb),能够在不诱导ADE的情况下中和所有四种DENV血清型.
在登革热的临床前模型中评估工程HuMAbs,特别是LALA-B3B9的治疗潜力.
评估Fc修改对抗体效应器功能和治疗疗效的影响.

主要方法:

产生LALA突变的人类单克隆抗体克隆B3B9 (LALA-B3B9 HuMAb).
使用ADE测定以不同的抗体度和补充蛋白质来评估中和ADE活动.
通过使用K562细胞和患者衍生的抗DENV抗体进行体外抑制增强试验来评估治疗疗效.

主要成果:

拉拉-B3B9HuMAb在没有诱导ADE的情况下,对所有四种DENV血清型都表现出强大的中和活性.
经Fc修饰的抗体 (LALA-B3B9和N297Q-B3B9) 显示了补充体独立活性,减少C1q结合不影响中和或增强.
LALA-B3B9和N297Q-B3B9 HuMAbs在体外有效地抑制了由人类抗DENV血清抗体诱导的ADE.

结论:

修改Fc的人类单克隆抗体,如LALA-B3B9,有效中和DENV并抑制ADE.
这些抗体为预防登革热的被动免疫疗法提供了一个有希望的策略,有可能克服与ADE相关的并发症.
这些工程抗体的进一步开发可能会导致登革热的新型治疗干预措施.

关键词:

交叉中和是可以实现的.登革热病毒感染者经过Fc修改后的人类单克隆抗体人类单克隆抗体

更多相关视频

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

相关概念视频

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Cross-reactivity

Cross-reactivity